Cite
Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis.
MLA
Ngo, Huy X., et al. “Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis.” Clinical Infectious Diseases, vol. 78, no. 6, June 2024, pp. 1680–89. EBSCOhost, https://doi.org/10.1093/cid/ciae119.
APA
Ngo, H. X., Xu, A. Y., Velásquez, G. E., Zhang, N., Chang, V. K., Kurbatova, E. V., Whitworth, W. C., Sizemore, E., Bryant, K., Carr, W., Weiner, M., Dooley, K. E., Engle, M., Dorman, S. E., Nahid, P., Swindells, S., Chaisson, R. E., Nsubuga, P., Lourens, M., & Dawson, R. (2024). Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis. Clinical Infectious Diseases, 78(6), 1680–1689. https://doi.org/10.1093/cid/ciae119
Chicago
Ngo, Huy X, Ava Y Xu, Gustavo E Velásquez, Nan Zhang, Vincent K Chang, Ekaterina V Kurbatova, William C Whitworth, et al. 2024. “Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis.” Clinical Infectious Diseases 78 (6): 1680–89. doi:10.1093/cid/ciae119.